晚期前列腺癌循环生物标志物共识声明
本文报告了晚期前列腺癌循环生物标志物的共识声明。18位国际专家通过改良Delphi流程对50个预设问题匿名投票,内容涵盖循环生物标志物的临床效用、未满足需求、最紧迫的血液分子检测及开发必要步骤。投票仅基于专家意见而非系统文献综述或Meta分析,结果可为未来循环生物标志物开发提供指导。
要点
- 18位国际专家通过改良Delphi流程对50个预设问题匿名投票形成共识。
- 共识聚焦循环生物标志物的临床效用、未满足需求、优先检测及开发步骤。
- 投票仅基于专家意见,非标准文献综述或Meta分析,结果支持程度不一。
核心结论
- 专家投票结果可为前列腺癌诊疗中循环生物标志物的未来发展提供指导。
- 共识会议特别强调可重复性与变异性研究的重要性,以及其他需专门设计试验解决的重要领域。
研究设计与样本
- 18位国际前列腺癌循环生物标志物领域专家组成专家组,制定议程与共识问题。
- 专家组通过改良Delphi流程开发50个预设问题,并进行公开但匿名的投票。
- 投票仅基于专家对预设主题的意见,而非标准文献综述或Meta分析。
主要发现
- 投票结果获得不同程度的支持,体现在本文措辞及补充材料提供的详细投票结果中。
- 共识会议识别出四个争议领域:循环生物标志物的已知临床效用、前列腺癌诊疗中未满足的临床需求、最紧迫的血液分子检测、开发循环生物标志物检测的必要步骤。
临床怎么用
- 原文未据此给出推荐。
- 作者指出,专家投票结果可为前列腺癌诊疗中循环生物标志物的未来发展提供指导。
局限性
- 投票仅基于专家对预设主题的意见,因此并非基于标准文献综述或Meta分析。
- 投票结果的支持程度不一,体现在本文措辞及补充材料的详细投票结果中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: In advanced prostate cancer (PC), there is increasing investigation of circulating biomarkers, including quantitation and characterization of circulating tumour cells and cell-free nucleic acids, for therapeutic monitoring and as prognostic and predictive biomarkers. However, there is a lack of consensus and standardisation regarding analyses, reporting, and integration of results into specific clinical contexts. A consensus meeting on circulating biomarkers was held to address these topics. OBJECTIVE: To present a report of the consensus statement on circulating biomarkers in advanced PC. EVIDENCE ACQUISITION: Four important areas of controversy in the field of circulating biomarkers in PC management were identified: known clinical utility of circulating biomarkers; unmet clinical needs for circulating biomarkers in PC care; most pressing blood-based molecular assays required; and essential steps for developing circulating biomarker assays. A panel of 18 international PC experts in the field of circulating biomarkers developed the programme and consensus questions. The panel voted publicly but anonymously on 50 predefined questions developed following a modified Delphi process. EVIDENCE SYNTHESIS: Voting was based solely on panellist opinions of the predefined topics and therefore not on a standard literature review or meta-analysis. The outcomes of the voting had varying degrees of support, as reflected in the wording of this article and in the detailed voting results provided in the Supplementary material. CONCLUSIONS: The expert voting results presented can guide the future development of circulating biomarkers for PC care. Notably, the consensus meeting highlighted the importance of reproducibility and variability studies, among other significant areas in need of trials specifically designed to address them. PATIENT SUMMARY: A panel of international experts met to discuss and vote on the use of different blood-based prostate cancer tests, and how they can be used to guide treatment and disease monitoring to deliver more precise and better patient care.
引用
- Sumanasuriya S, Omlin A, Armstrong A, et al. Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer. Eur Urol Oncol. 2018. PMID: 31100240. doi:10.1016/j.euo.2018.02.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。